The global genetic counseling services market was valued at USD 1.29 billion in 2025. The market is estimated at USD 1.42 billion in 2026 and is projected to reach USD 3.68 billion by 2036, at a CAGR of 10.0% during the forecast period 2026-2036. This report assesses the counseling workforce, service delivery models, reimbursement and licensure policy, the value chain, pricing and session economics, the competitive landscape, and future growth opportunities.
The market covers professional services that help patients and families weigh whether to have genetic testing, understand what results mean, and decide what to do next. It includes pre-test counseling and consent, post-test result disclosure and management advice, cascade counseling for at-risk relatives, and follow-up when variant classifications change, delivered in person, by video, or by telephone. Test revenue, physician-billed genetics consultations, laboratory interpretation without patient contact, and counselor training are excluded.
According to the National Society of Genetic Counselors (NSGC), the number of counselors certified by the American Board of Genetic Counseling reached 5,629 in 2021, compared with 1,155 in 1999, with roughly one clinical genetic counselor for every 100,000 people. The NSGC's 2023 Professional Status Survey, with more than 3,000 respondents, found that 82% of genetic counselors surveyed delivered care by video and that cancer genetics was the largest specialty, accounting for 34% of the profession. The Access to Genetic Counselor Services Act of 2026 (S. 3607), introduced in the U.S. Senate in January 2026, proposes adding genetic counseling as a Medicare Part B benefit and recognizing licensed or board-certified counselors as eligible providers for services from January 1, 2027.
Because genetic counselors are not yet recognized as Medicare providers in the U.S., and direct reimbursement is missing in most other jurisdictions, counseling is often funded by hospital genetics departments, built into laboratory test prices, or offered to support test ordering, which limits the number of settings that employ counselors and restrains the market. Licensure also differs by state, and not every state licenses genetic counselors, so national telehealth providers must hold many licenses and match counselors to patients by location; in many other countries, clinical geneticists or nurses deliver counseling instead of a separate profession. Providers also struggle to prove economic value to payers, since savings fall across different budgets and long time frames, and counseling is still poorly built into ordering workflows.
Scalable models that pair digital education with specialist counseling, which let a fixed workforce support much higher test volumes, are a major opportunity. Rare disease and targeted therapy counseling, where a molecular diagnosis leads to treatment and attracts pharmaceutical funding, cascade testing programs that reach at-risk relatives, and expansion into pharmacogenomics, cardiovascular genetics, and primary care also offer strong potential. Key trends include a move away from specialist referral toward tiered models built into testing pathways, telehealth becoming the default delivery mode, and growing funding of counseling by laboratories and pharmaceutical companies.
By service type, the genetic counseling services market is segmented into pre-test counseling, post-test counseling, cascade testing & family counseling, and variant reinterpretation & follow-up services. Post-test counseling is expected to hold the largest share in 2026, as disclosing results means explaining pathogenic and uncertain variants and secondary findings, these conversations shape surveillance, treatment, and reproductive choices, and post-test sessions run longer. Cascade testing & family counseling is projected to record the highest CAGR, since every identified variant implies risk for several relatives, current uptake of cascade testing is low, and payers want to find carriers before disease develops. Variant reinterpretation and follow-up services are also set to grow well as the backlog of uncertain results needs regular review.
By specialty, the genetic counseling services market is segmented into oncology genetic counseling, reproductive & prenatal genetic counseling, rare & undiagnosed disease counseling, cardiovascular genetic counseling, pharmacogenomic counseling, and other specialties such as neurogenetics, metabolic disease, and population screening. In 2026, oncology genetic counseling is set to hold the largest share, reflecting high volumes of hereditary cancer and tumor genomic testing, the direct effect of hereditary cancer results on surveillance and risk-reducing surgery, the implications for family members, and the large share of counselors working in cancer genetics. Rare & undiagnosed disease counseling is projected to grow at the highest CAGR, as exome and genome sequencing become first-line diagnostic tools, genetically targeted therapies link diagnosis to treatment, and companies such as Genome Medical are refocusing on rare disease.
By delivery mode, the genetic counseling services market is segmented into telehealth (audiovisual telehealth and telephone & asynchronous delivery) and in-person. Telehealth is expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period, because most counselors already use video, nearly all patient-facing counselors combine several delivery models, counseling rarely needs a physical examination, and telehealth providers can reach patients in all 50 U.S. states. In-person counseling remains important in prenatal care, pediatric and rare disease assessments, and for patients without reliable connectivity.
By provider type, the genetic counseling services market is segmented into hospital & health system genetics services, laboratory-employed counseling services, independent telehealth counseling providers, and academic medical center genetics services. Hospital & health system genetics services are expected to hold the largest share in 2026, as most clinical genetics work takes place in hospitals, counseling is tied to oncology, cardiology, and reproductive services, and health systems employ most clinical counselors. Independent telehealth counseling providers are projected to record the highest CAGR, supported by their national reach, contracts with health plans, employers, laboratories, and drug developers, and the capacity they supply to understaffed health systems; Genome Medical, for example, has reported in-network health plan contracts reaching over 148 million members.
By end user, the genetic counseling services market is segmented into patients & families, hospitals & health systems, clinical laboratories, payers & employers, and pharmaceutical & biotechnology companies. Hospitals & health systems are expected to account for the largest share in 2026, measured by the party that buys or funds the service, since they fund genetics departments and embedded counselors and build counseling into oncology and reproductive pathways. Pharmaceutical & biotechnology companies are projected to grow at the highest CAGR, driven by funding for diagnosis, counseling, and trial identification programs in rare diseases with genetically targeted therapies and by the use of counseling services in clinical trial recruitment.
North America is expected to lead the global genetic counseling services market in 2026, owing to the concentration of certified genetic counselors, high genomic testing volumes, independent telehealth providers that operate across the country, and the prospect of direct Medicare payment for counselor services. Europe holds a significant position, supported by national genomic medicine programs that build counseling into set care pathways, established clinical genetics services in academic centers, and growth in hereditary cancer and rare disease testing. Because counseling in much of Europe is provided by clinical geneticists and specialist nurses within public health services, growth there depends mainly on program expansion rather than a commercial services market.
Asia-Pacific is expected to be the fastest-growing region through 2036, supported by fast-rising genomic testing across China, Japan, South Korea, India, and Australia, government-backed genomic medicine and cancer genomics programs, newly launched counselor training courses, and a very low number of counselors per head of population, which allows rapid growth from a small base. Smaller shares are held by Latin America and the Middle East & Africa; oncology and reproductive testing support demand in Brazil and Mexico, while national genome programs and the high burden of consanguinity-related genetic conditions are encouraging investment in counseling capacity in Saudi Arabia and the UAE.
The genetic counseling services market is fragmented, with hospital and academic genetics departments, which are not commercial competitors, delivering most counseling, while laboratories such as Labcorp, Quest Diagnostics, Myriad Genetics, Natera, GeneDx, and Exact Sciences run their own counseling teams and a smaller group of telehealth specialists, including Genome Medical, InformedDNA, and Genetic Support Foundation, operate as commercial service businesses. Providers compete on counselor availability, specialty depth, licensure coverage, workflow integration, payer contracts, and patient experience. Commercial providers are widening licensure, signing health plan and employer contracts, focusing on high-value indications, and adding trial recruitment and digital education services. Genome Medical marked its tenth anniversary in July 2026, reporting more than 250,000 counseling sessions delivered, after announcing a strategic shift toward rare disease in early 2025.
Key companies profiled in the report include Genome Medical, Inc. (U.S.), InformedDNA (U.S.), Genetic Support Foundation (U.S.), Laboratory Corporation of America Holdings (U.S.), Quest Diagnostics Incorporated (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), GeneDx Holdings Corp. (U.S.), Exact Sciences Corporation (U.S.), and Fulgent Genetics, Inc. (U.S.).
The market covers professional services that help patients and families weigh whether to have genetic testing, understand what results mean, and decide what to do next. It includes pre-test counseling and consent, post-test result disclosure and management advice, cascade counseling for at-risk relatives, and follow-up when variant classifications change, delivered in person, by video, or by telephone. Test revenue, physician-billed genetics consultations, laboratory interpretation without patient contact, and counselor training are excluded.
According to the National Society of Genetic Counselors (NSGC), the number of counselors certified by the American Board of Genetic Counseling reached 5,629 in 2021, compared with 1,155 in 1999, with roughly one clinical genetic counselor for every 100,000 people. The NSGC's 2023 Professional Status Survey, with more than 3,000 respondents, found that 82% of genetic counselors surveyed delivered care by video and that cancer genetics was the largest specialty, accounting for 34% of the profession. The Access to Genetic Counselor Services Act of 2026 (S. 3607), introduced in the U.S. Senate in January 2026, proposes adding genetic counseling as a Medicare Part B benefit and recognizing licensed or board-certified counselors as eligible providers for services from January 1, 2027.
Market Dynamics
Rising genomic testing volumes are a major driver of the genetic counseling services market, because counseling demand follows the number of tests ordered. Hereditary cancer panels, carrier and prenatal screening, rare disease sequencing, and pharmacogenomic tests are now ordered routinely by oncologists, obstetricians, cardiologists, and family doctors, and blood-based screening adds very large eligible populations. Results are also more complex, as broad panels, exomes, and genomes produce uncertain variants and secondary findings that most non-specialist clinicians are not trained to explain, and later reclassification requires recontact. The shortage of counselors is pushing health systems and laboratories to invest in digital and group education before testing, counseling assistants, risk-based triage, and outsourced capacity, while telehealth removes distance as a barrier and lets providers operate nationally.Because genetic counselors are not yet recognized as Medicare providers in the U.S., and direct reimbursement is missing in most other jurisdictions, counseling is often funded by hospital genetics departments, built into laboratory test prices, or offered to support test ordering, which limits the number of settings that employ counselors and restrains the market. Licensure also differs by state, and not every state licenses genetic counselors, so national telehealth providers must hold many licenses and match counselors to patients by location; in many other countries, clinical geneticists or nurses deliver counseling instead of a separate profession. Providers also struggle to prove economic value to payers, since savings fall across different budgets and long time frames, and counseling is still poorly built into ordering workflows.
Scalable models that pair digital education with specialist counseling, which let a fixed workforce support much higher test volumes, are a major opportunity. Rare disease and targeted therapy counseling, where a molecular diagnosis leads to treatment and attracts pharmaceutical funding, cascade testing programs that reach at-risk relatives, and expansion into pharmacogenomics, cardiovascular genetics, and primary care also offer strong potential. Key trends include a move away from specialist referral toward tiered models built into testing pathways, telehealth becoming the default delivery mode, and growing funding of counseling by laboratories and pharmaceutical companies.
Segment Analysis
The report analyzes the market by service type, specialty, delivery mode, provider type, end user, and geography, helping stakeholders identify the most attractive areas for service development, partnerships, and investment.By service type, the genetic counseling services market is segmented into pre-test counseling, post-test counseling, cascade testing & family counseling, and variant reinterpretation & follow-up services. Post-test counseling is expected to hold the largest share in 2026, as disclosing results means explaining pathogenic and uncertain variants and secondary findings, these conversations shape surveillance, treatment, and reproductive choices, and post-test sessions run longer. Cascade testing & family counseling is projected to record the highest CAGR, since every identified variant implies risk for several relatives, current uptake of cascade testing is low, and payers want to find carriers before disease develops. Variant reinterpretation and follow-up services are also set to grow well as the backlog of uncertain results needs regular review.
By specialty, the genetic counseling services market is segmented into oncology genetic counseling, reproductive & prenatal genetic counseling, rare & undiagnosed disease counseling, cardiovascular genetic counseling, pharmacogenomic counseling, and other specialties such as neurogenetics, metabolic disease, and population screening. In 2026, oncology genetic counseling is set to hold the largest share, reflecting high volumes of hereditary cancer and tumor genomic testing, the direct effect of hereditary cancer results on surveillance and risk-reducing surgery, the implications for family members, and the large share of counselors working in cancer genetics. Rare & undiagnosed disease counseling is projected to grow at the highest CAGR, as exome and genome sequencing become first-line diagnostic tools, genetically targeted therapies link diagnosis to treatment, and companies such as Genome Medical are refocusing on rare disease.
By delivery mode, the genetic counseling services market is segmented into telehealth (audiovisual telehealth and telephone & asynchronous delivery) and in-person. Telehealth is expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period, because most counselors already use video, nearly all patient-facing counselors combine several delivery models, counseling rarely needs a physical examination, and telehealth providers can reach patients in all 50 U.S. states. In-person counseling remains important in prenatal care, pediatric and rare disease assessments, and for patients without reliable connectivity.
By provider type, the genetic counseling services market is segmented into hospital & health system genetics services, laboratory-employed counseling services, independent telehealth counseling providers, and academic medical center genetics services. Hospital & health system genetics services are expected to hold the largest share in 2026, as most clinical genetics work takes place in hospitals, counseling is tied to oncology, cardiology, and reproductive services, and health systems employ most clinical counselors. Independent telehealth counseling providers are projected to record the highest CAGR, supported by their national reach, contracts with health plans, employers, laboratories, and drug developers, and the capacity they supply to understaffed health systems; Genome Medical, for example, has reported in-network health plan contracts reaching over 148 million members.
By end user, the genetic counseling services market is segmented into patients & families, hospitals & health systems, clinical laboratories, payers & employers, and pharmaceutical & biotechnology companies. Hospitals & health systems are expected to account for the largest share in 2026, measured by the party that buys or funds the service, since they fund genetics departments and embedded counselors and build counseling into oncology and reproductive pathways. Pharmaceutical & biotechnology companies are projected to grow at the highest CAGR, driven by funding for diagnosis, counseling, and trial identification programs in rare diseases with genetically targeted therapies and by the use of counseling services in clinical trial recruitment.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 17 countries and four rest-of-region groups. The regional analysis of the genetic counseling services market considers counselor density, testing volumes, reimbursement and licensure rules, and national genomics programs.North America is expected to lead the global genetic counseling services market in 2026, owing to the concentration of certified genetic counselors, high genomic testing volumes, independent telehealth providers that operate across the country, and the prospect of direct Medicare payment for counselor services. Europe holds a significant position, supported by national genomic medicine programs that build counseling into set care pathways, established clinical genetics services in academic centers, and growth in hereditary cancer and rare disease testing. Because counseling in much of Europe is provided by clinical geneticists and specialist nurses within public health services, growth there depends mainly on program expansion rather than a commercial services market.
Asia-Pacific is expected to be the fastest-growing region through 2036, supported by fast-rising genomic testing across China, Japan, South Korea, India, and Australia, government-backed genomic medicine and cancer genomics programs, newly launched counselor training courses, and a very low number of counselors per head of population, which allows rapid growth from a small base. Smaller shares are held by Latin America and the Middle East & Africa; oncology and reproductive testing support demand in Brazil and Mexico, while national genome programs and the high burden of consanguinity-related genetic conditions are encouraging investment in counseling capacity in Saudi Arabia and the UAE.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share and rank analysis by key player for 2025. Company profiles include business overviews, financial overviews, service portfolios, delivery models and coverage, strategic developments, and SWOT analyses.The genetic counseling services market is fragmented, with hospital and academic genetics departments, which are not commercial competitors, delivering most counseling, while laboratories such as Labcorp, Quest Diagnostics, Myriad Genetics, Natera, GeneDx, and Exact Sciences run their own counseling teams and a smaller group of telehealth specialists, including Genome Medical, InformedDNA, and Genetic Support Foundation, operate as commercial service businesses. Providers compete on counselor availability, specialty depth, licensure coverage, workflow integration, payer contracts, and patient experience. Commercial providers are widening licensure, signing health plan and employer contracts, focusing on high-value indications, and adding trial recruitment and digital education services. Genome Medical marked its tenth anniversary in July 2026, reporting more than 250,000 counseling sessions delivered, after announcing a strategic shift toward rare disease in early 2025.
Key companies profiled in the report include Genome Medical, Inc. (U.S.), InformedDNA (U.S.), Genetic Support Foundation (U.S.), Laboratory Corporation of America Holdings (U.S.), Quest Diagnostics Incorporated (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), GeneDx Holdings Corp. (U.S.), Exact Sciences Corporation (U.S.), and Fulgent Genetics, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global genetic counseling services market.
- Explains how testing volumes, result complexity, workforce shortages, and telehealth are shaping demand for counseling.
- Assesses the impact of Medicare reimbursement reform, state licensure, and payer value requirements on providers.
- Identifies high-growth opportunities across service type, specialty, delivery mode, provider type, end user, and region.
- Tracks the shift to tiered and embedded service models, digital pre-test education, and counselor-extender roles.
- Benchmarks leading providers on service portfolio, delivery model, licensure coverage, and strategic developments.
- Supports service design, payer contracting, partnership, and market entry decisions for counseling providers, laboratories, health systems, and investors.
Key Questions Answered
- How big is the global genetic counseling services market today, and how will it grow through 2036?
- How large is the genetic counselor workforce, and how is the shortage shaping service models?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- What would the Access to Genetic Counselor Services Act mean for Medicare reimbursement of counseling?
- Which service types, specialties, delivery modes, provider types, and end users will grow the fastest?
- How has telehealth changed access to genetic counseling?
- Why is rare disease counseling attracting pharmaceutical funding?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading providers, and what strategies are they using to strengthen their position?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Genetic Counseling Services Market Assessment, by Service Type
6. Genetic Counseling Services Market Assessment, by Specialty
7. Genetic Counseling Services Market Assessment, by Delivery Mode
8. Genetic Counseling Services Market Assessment, by Provider Type
9. Genetic Counseling Services Market Assessment, by End User
10. Genetic Counseling Services Market Assessment, by Geography
11. Competition Analysis
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Genome Medical, Inc.
- InformedDNA
- Genetic Support Foundation
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Myriad Genetics, Inc.
- Natera, Inc.
- GeneDx Holdings Corp.
- Exact Sciences Corporation
- Fulgent Genetics, Inc.
